DK3145945T3 - Hidtil ukendte specifikt bindende polypeptider og anvendelser deraf - Google Patents
Hidtil ukendte specifikt bindende polypeptider og anvendelser deraf Download PDFInfo
- Publication number
- DK3145945T3 DK3145945T3 DK15727573.6T DK15727573T DK3145945T3 DK 3145945 T3 DK3145945 T3 DK 3145945T3 DK 15727573 T DK15727573 T DK 15727573T DK 3145945 T3 DK3145945 T3 DK 3145945T3
- Authority
- DK
- Denmark
- Prior art keywords
- unknown
- binding polypeptides
- specificly
- specificly binding
- polypeptides
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/525—Tumor necrosis factor [TNF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14169488 | 2014-05-22 | ||
| PCT/EP2015/061034 WO2015177175A2 (en) | 2014-05-22 | 2015-05-20 | Novel specific-binding polypeptides and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3145945T3 true DK3145945T3 (da) | 2020-09-28 |
Family
ID=50771150
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15727573.6T DK3145945T3 (da) | 2014-05-22 | 2015-05-20 | Hidtil ukendte specifikt bindende polypeptider og anvendelser deraf |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10774119B2 (enExample) |
| EP (2) | EP3145945B1 (enExample) |
| JP (2) | JP6753784B2 (enExample) |
| KR (1) | KR20170004011A (enExample) |
| CN (2) | CN113621050A (enExample) |
| AU (2) | AU2015261968B2 (enExample) |
| BR (1) | BR112016027024A2 (enExample) |
| CA (2) | CA3170782A1 (enExample) |
| DK (1) | DK3145945T3 (enExample) |
| ES (1) | ES2823563T3 (enExample) |
| MX (2) | MX384363B (enExample) |
| RU (1) | RU2723034C2 (enExample) |
| SG (2) | SG10201912019WA (enExample) |
| WO (1) | WO2015177175A2 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2920202B1 (en) | 2012-11-19 | 2018-08-29 | Pieris Pharmaceuticals GmbH | Novel specific-binding polypeptides and uses thereof |
| EP3145945B1 (en) | 2014-05-22 | 2020-07-15 | Pieris Pharmaceuticals GmbH | Novel specific-binding polypeptides and uses thereof |
| US10703810B2 (en) * | 2015-11-30 | 2020-07-07 | Pieris Australia Pty Ltd. | Fusion polypeptides which bind vascular endothelial growth factor a (VEGF-A) and angiopoietin-2 (Ang-2) |
| RS63818B1 (sr) | 2017-02-17 | 2023-01-31 | Denali Therapeutics Inc | Konstruisani polipeptidi za vezivanje za receptor transferina |
| CN111164104A (zh) | 2017-08-09 | 2020-05-15 | 麻省理工学院 | 白蛋白结合肽缀合物及其方法 |
| WO2019032955A1 (en) * | 2017-08-10 | 2019-02-14 | Denali Therapeutics Inc. | MODIFIED TRANSFERRIN RECEPTOR BINDING POLYPEPTIDES |
| JP7516250B2 (ja) | 2018-03-05 | 2024-07-16 | ヤンセン バイオテツク，インコーポレーテツド | 抗ｉｌ－２３特異的抗体を用いたクローン病の治療方法 |
| CN112513099A (zh) * | 2018-05-31 | 2021-03-16 | 香港理工大学 | 用于癌症、肥胖症、代谢紊乱和相关并发症及合并症的精氨酸耗竭剂的组合物和应用 |
| EP3599245A1 (en) * | 2018-07-27 | 2020-01-29 | Dompé farmaceutici S.p.A. | Il-17a binding polypeptides and medical uses thereof |
| CN109180789B (zh) * | 2018-09-27 | 2022-08-19 | 上海揽微赛尔生物科技有限公司 | 一种寡肽及制药应用 |
| CN109096374B (zh) * | 2018-09-27 | 2022-11-18 | 深圳乐土沃森精准医疗有限公司 | 一种抑制肺癌转移的合成寡肽 |
| CN109206485B (zh) * | 2018-09-27 | 2022-04-08 | 山东聚胜生物科技有限公司 | 一种防治肺癌转移的寡肽 |
| CN109096373B (zh) * | 2018-09-27 | 2022-06-21 | 江苏亨瑞生物医药科技有限公司 | 合成寡肽及其用途 |
| CN113939307A (zh) | 2019-03-29 | 2022-01-14 | 皮里斯制药有限公司 | 脂质运载蛋白突变蛋白的吸入施用 |
| CA3181949A1 (en) * | 2020-05-05 | 2021-11-11 | Janssen Biotech, Inc. | Methods of treating crohn's disease with anti-il23 specific antibody |
| IL311003A (en) | 2021-08-25 | 2024-04-01 | Denali Therapeutics Inc | Anti-2HER antibodies and methods of using them |
| CN114805546B (zh) * | 2022-06-08 | 2024-05-28 | 宁波市健康口腔医学研究院 | 一种检测口腔癌的t细胞表位多肽及其应用 |
| WO2025171006A1 (en) | 2024-02-06 | 2025-08-14 | Paragon Therapeutics, Inc. | Il-23 binding protein compositions and methods of use |
| AU2025218720A1 (en) | 2024-02-06 | 2026-05-21 | Paragon Therapeutics, Inc. | Il-23 antibody compositions and methods of use |
| WO2025226984A1 (en) * | 2024-04-24 | 2025-10-30 | Mopac Biologics, Inc. | Human il-17 binding polypeptides |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2032831T5 (es) | 1986-08-19 | 2001-02-16 | Genentech Inc | Dispositivo y dispersion para suministro intrapulmonar de factores de crecimiento polipeptidos y citoquinas. |
| JPH01215289A (ja) | 1988-02-22 | 1989-08-29 | Toa Nenryo Kogyo Kk | 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法 |
| FR2649991B2 (fr) | 1988-08-05 | 1994-03-04 | Rhone Poulenc Sante | Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces |
| US5728553A (en) | 1992-09-23 | 1998-03-17 | Delta Biotechnology Limited | High purity albumin and method of producing |
| AU696387B2 (en) | 1994-05-18 | 1998-09-10 | Inhale Therapeutic Systems, Inc. | Methods and compositions for the dry powder formulation of interferons |
| DE4417598A1 (de) | 1994-05-19 | 1995-12-14 | Max Planck Gesellschaft | Verwendung des Tetracyclinpromotors zur stringent regulierten Produktion von rekombinanten Proteinen in prokaryontischen Zellen |
| WO1996023879A1 (en) | 1995-01-30 | 1996-08-08 | Terrapin Technologies, Inc. | Glubodies - multiplicities of proteins capable of binding a variety of small molecules |
| US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| US6620413B1 (en) | 1995-12-27 | 2003-09-16 | Genentech, Inc. | OB protein-polymer chimeras |
| DE19641876B4 (de) | 1996-10-10 | 2011-09-29 | Iba Gmbh | Streptavidinmuteine |
| WO1998016873A1 (en) | 1996-10-14 | 1998-04-23 | Firm Forsat Ltd. | Method for preparing dispersions of chromogenic components |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| CA2233725A1 (en) | 1998-03-31 | 1999-09-30 | Hemosol Inc. | Hemoglobin-hydroxyethyl starch complexes |
| JP3839667B2 (ja) | 1998-06-08 | 2006-11-01 | エフ．ホフマン−ラ ロシュ アーゲー | 慢性Ｃ型肝炎の処置のためのＰｅｇ−ＩＮＦ−アルファ及びリバビリンの使用 |
| US6403564B1 (en) | 1998-10-16 | 2002-06-11 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
| DE19926068C1 (de) | 1999-06-08 | 2001-01-11 | Arne Skerra | Muteine des Bilin-Bindungsproteins |
| US7211395B2 (en) | 2001-03-09 | 2007-05-01 | Dyax Corp. | Serum albumin binding moieties |
| US7118915B2 (en) | 2001-09-27 | 2006-10-10 | Pieris Proteolab Ag | Muteins of apolipoprotein D |
| WO2003029462A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
| WO2005019255A1 (en) | 2003-08-25 | 2005-03-03 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| US7691970B2 (en) | 2003-08-25 | 2010-04-06 | Pieris Ag | Muteins of a bilin-binding protein with affinity for a given target |
| JP2007284351A (ja) | 2004-07-27 | 2007-11-01 | Osaka Bioscience Institute | アミロイド蛋白質の凝集を抑制する物質とその作用 |
| US7892827B2 (en) | 2004-11-26 | 2011-02-22 | Pieris Ag | Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4) |
| AU2006294644A1 (en) | 2005-09-27 | 2007-04-05 | Amunix, Inc. | Proteinaceous pharmaceuticals and uses thereof |
| JP2009540018A (ja) | 2006-06-13 | 2009-11-19 | ザイモジェネティクス， インコーポレイテッド | Ｉｌ−１７およびｉｌ−２３アンタゴニストならびにその使用方法 |
| TW200815469A (en) * | 2006-06-23 | 2008-04-01 | Astrazeneca Ab | Compounds |
| DE602007009995D1 (de) | 2006-08-01 | 2010-12-02 | Pieris Ag | Muteine von tearlipocalin und verfahren zu deren gewinnung |
| CN101516907B (zh) * | 2006-08-01 | 2015-08-26 | 皮里斯股份公司 | 泪液脂质运载蛋白的突变蛋白及其获得方法 |
| HUE042172T2 (hu) | 2007-02-23 | 2019-06-28 | Merck Sharp & Dohme | Genetikailag elõállított anti-il-23P19 antitestek |
| AR068723A1 (es) | 2007-10-05 | 2009-12-02 | Glaxo Group Ltd | Proteina que se une a antigenos que se une a il-23 humana y sus usos |
| EP2225268B1 (en) | 2007-10-19 | 2012-08-29 | Abbott Laboratories | Immunoassays and kits for the detection of ngal |
| EP2245054B1 (en) * | 2008-01-30 | 2018-11-28 | Pieris Pharmaceuticals GmbH | Muteins of tear lipocalin having affinity to human c-met receptor tyrosine kinase and methods for obtaining the same |
| US8420051B2 (en) | 2008-06-24 | 2013-04-16 | Technische Universitaet Meunchen | Muteins of hNGAL and related proteins with affinity for a given target |
| EP2330897A4 (en) * | 2008-09-18 | 2013-11-27 | Univ Columbia | NGAL-BINDING SIDEROPHORES AND THEIR USE FOR THE TREATMENT OF IRON DEFICIENCY AND IRON SURPLUS |
| BR112012013662B1 (pt) | 2009-12-07 | 2022-08-02 | Pieris Pharmaceuticals Gmbh | Muteínas de lipocalina associada à gelatinase de neutrófilo humano (lcn2, hngal), seu uso e seus métodos de geração e produção, molécula de ácido nucleico, célula hospedeira, composição farmacêutica e kit de diagnóstico ou analítico |
| AU2011263786B2 (en) | 2010-06-08 | 2014-11-13 | Astrazeneca Ab | Tear lipocalin muteins binding IL-4 R alpha |
| BR112013000452A2 (pt) | 2010-07-09 | 2020-02-11 | Affibody Ab | Polipeptídeo de ligação de albumina, proteína de fusão ou conjugado, polinucleotídeo, método para produzir um polipeptídeo, composição, método para a preparação de uma composição, e, método para aumentar a solubilidade de um composto |
| AU2011290751B2 (en) | 2010-08-16 | 2015-08-13 | Pieris Ag | Binding proteins for Hepcidin |
| CA2817779C (en) | 2010-11-15 | 2019-02-19 | Pieris Pharmaceuticals Gmbh | Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3) |
| GB201100282D0 (en) * | 2011-01-07 | 2011-02-23 | Ucb Pharma Sa | Biological methods |
| UA117218C2 (uk) | 2011-05-05 | 2018-07-10 | Мерк Патент Гмбх | Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f |
| EP3453400B1 (en) | 2011-12-13 | 2021-01-20 | Pieris Pharmaceuticals GmbH | Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors |
| EP2920202B1 (en) | 2012-11-19 | 2018-08-29 | Pieris Pharmaceuticals GmbH | Novel specific-binding polypeptides and uses thereof |
| AU2015205530B8 (en) * | 2014-01-13 | 2019-09-19 | Pieris Pharmaceuticals Gmbh | Multi-specific polypeptide useful for localized tumor immunomodulation |
| EP3145945B1 (en) | 2014-05-22 | 2020-07-15 | Pieris Pharmaceuticals GmbH | Novel specific-binding polypeptides and uses thereof |
| SG11201705278QA (en) | 2015-01-28 | 2017-07-28 | Pieris Pharmaceuticals Gmbh | Novel proteins specific for angiogenesis |
| EP3259282A1 (en) | 2015-02-18 | 2017-12-27 | Sanofi | Novel proteins specific for pyoverdine and pyochelin |
| PH12017501583B1 (en) | 2015-05-04 | 2023-01-20 | Pieris Pharmaceuticals Gmbh | Novel proteins specific for cd137 |
| EP3298029A1 (en) | 2015-05-18 | 2018-03-28 | Pieris Pharmaceuticals GmbH | Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3) |
| TW201725212A (zh) | 2015-12-10 | 2017-07-16 | 第一三共股份有限公司 | 特異性於降鈣素基因相關胜肽的新穎蛋白 |
-
2015
- 2015-05-20 EP EP15727573.6A patent/EP3145945B1/en active Active
- 2015-05-20 KR KR1020167035964A patent/KR20170004011A/ko not_active Ceased
- 2015-05-20 CA CA3170782A patent/CA3170782A1/en active Pending
- 2015-05-20 RU RU2016149596A patent/RU2723034C2/ru active
- 2015-05-20 CN CN202110703906.XA patent/CN113621050A/zh active Pending
- 2015-05-20 US US15/312,094 patent/US10774119B2/en not_active Expired - Fee Related
- 2015-05-20 ES ES15727573T patent/ES2823563T3/es active Active
- 2015-05-20 CA CA2949405A patent/CA2949405C/en active Active
- 2015-05-20 AU AU2015261968A patent/AU2015261968B2/en not_active Ceased
- 2015-05-20 JP JP2016568907A patent/JP6753784B2/ja not_active Expired - Fee Related
- 2015-05-20 WO PCT/EP2015/061034 patent/WO2015177175A2/en not_active Ceased
- 2015-05-20 MX MX2016015235A patent/MX384363B/es unknown
- 2015-05-20 SG SG10201912019WA patent/SG10201912019WA/en unknown
- 2015-05-20 CN CN201580040321.7A patent/CN106573964B/zh not_active Expired - Fee Related
- 2015-05-20 EP EP20185401.5A patent/EP3789397B1/en active Active
- 2015-05-20 DK DK15727573.6T patent/DK3145945T3/da active
- 2015-05-20 SG SG11201609274SA patent/SG11201609274SA/en unknown
- 2015-05-20 BR BR112016027024A patent/BR112016027024A2/pt not_active Application Discontinuation
-
2016
- 2016-11-18 MX MX2021008318A patent/MX2021008318A/es unknown
-
2019
- 2019-02-13 AU AU2019201007A patent/AU2019201007B2/en not_active Ceased
-
2020
- 2020-08-06 US US16/987,218 patent/US11345728B2/en not_active Expired - Fee Related
- 2020-08-20 JP JP2020139064A patent/JP7084965B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL282704A (en) | De novo binding domain containing polypeptides and uses thereof | |
| IL285286A (en) | Transposase polypeptides and uses thereof | |
| DK3303379T3 (da) | Tigit-bindende midler og anvendelser deraf | |
| DK3157552T3 (da) | Syntac-polypeptider og anvendelser deraf | |
| DK3412302T3 (da) | Modificerede fgf-21-polypeptider og anvendelser deraf | |
| HRP20260151T1 (hr) | Modificirani polipeptidi i njihova uporaba | |
| IL246921B (en) | Binding proteins and methods of use thereof | |
| DK3390444T3 (da) | Anti-tl1a-antigenbindende proteiner og anvendelser deraf | |
| DK3229838T3 (da) | Anti-C10orf54-antistoffer og anvendelser deraf | |
| DK3126388T3 (da) | Anti-EGFRvIII-antistoffer og anvendelser deraf | |
| DK3221347T3 (da) | Muterede immunoglobulin-bindende polypeptider | |
| DK3235830T3 (da) | Interleukin-15-proteinkompleks og anvendelse deraf | |
| DK3218358T3 (da) | Ifluorometyl-aminopyridiner og difluorometyl-aminopyrimidiner | |
| DK3402821T3 (da) | Psma-bindende antistof og anvendelser deraf | |
| DK3283106T3 (da) | Terapeutiske antistoffer og anvendelser deraf | |
| DK3532499T3 (da) | ANTI-IL-33-antistoffer og anvendelser deraf | |
| DK3015526T3 (da) | Hydrofluorolefinbaseret sammensætning og anvendelse deraf | |
| DK3319612T3 (da) | Oxysteroler og fremgansmåder til anvendelse derfor | |
| DK3161139T3 (da) | Tlr-4-specifikke aptamerer og anvendelser heraf | |
| DK3233105T3 (da) | Hidtil ukendt kombination og anvendelse | |
| IL250796A0 (en) | Binding proteins specific for lox1 and uses thereof | |
| DK3290441T3 (da) | Rgma-bindingsprotein og anvendelse deraf | |
| DK3337506T3 (da) | Kombinationer og anvendelser deraf | |
| DK3321279T3 (da) | Exenatidmodificeringsmiddel og anvendelse deraf | |
| DK3365321T3 (da) | Solabegron-zwitterion og anvendelser deraf |